Abstract
The Multiple Sclerosis (MS) therapeutic market will experience a significant shift in power in the next five years. The current market leaders, Interferons and Copaxone, could lose their dominance to novel orally formulated and biologic treatments that offer superior convenience, efficacy, and quality of life for MS patients. The strong trend in the increased competitiveness of the oral class is also validated by the R&D efforts of the MS market leader, Biogen Idec (Avonex), who is investing heavily in 2 programs for oral drugs in phase 2 (CDP-323) and phase 3 (BG-12).
It is critical that stakeholders currently competing or considering entry into this hyper-competitive therapeutic market are well-informed with the latest intelligence on clinical trials of competitors of today and the future.
Austin Research Group' s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease including:
- Epidemiology
- Patient Segmentation
- Clinical endpoints
The Trial TRAX brief also contains analysis of the clinical landscape which comprises assessments including:
- % utilization of key clinical endpoints
- Number of ongoing trials (by phase of development)
- Key companies sponsoring clinical trials
Key data points from competitor clinical trials presented in the briefing include:
- Study Drug
- Mechanism of Action
- Company-Sponsor
- Phase of Development
- Number of Patients
- Study Design
- Primary Endpoints
- Study Start Date
The brief' s reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs. The information contained within the report is updated on a quarterly basis to ensure accuracy, relevancy, and timeliness of the intelligence.
Clients utilize the Trial TRAX briefing reports to:
- Monitor clinical development programs of competitors
- Evaluate depth and breadth of competitive landscape
- Identify potential patient recruitment challenges
- Benchmark competitor clinical trial designs
Table of Contents
Section 1: Executive Summary
- Multiple Sclerosis Disease Overview: Background
- Clinical Courses of Multiple Sclerosis
- Clinical Endpoints in Multiple Sclerosis Trials
- Overview of Clinical Landscape
- Key Players in Multiple Sclerosis R&D
- Competitor Clinical Trial MAP-The Orals
- Competitor Clinical Trial MAP-Biologics
Section 2: Ongoing Clinical Trial in Rheumatoid Arthritis
- Phase I & Phase II: Competitive Clinical Trial Details
- Phase III: Competitive Clinical Trial Details
- Phase IV: Competitive Clinical Trial Details
Section 3: Appendix
- Disclaimer
- Report Licensing
